ROCHESTER, Minn., January 07, 2025--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company revolutionizing healthcare through its exosome-based technology, announced today that its ...

RION's Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU). Diabetic ...

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome therapeutics, announced today the first subject was dosed in the Phase 2 clinical ...

ROCHESTER, Minn., March 11, 2025--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, today announced the enrollment of the first ...

"I have always been fascinated by innovative, disruptive technologies that are accessible and affordable. Once I started my journey in the PEP, I had the choice of taking courses that served my need ...